Naringenin decreases total cell viability. by Lauren A. Eanes (20995499)

C-terminal tagging of NCAPH2 can either increase or decrease protein expression. by Gillian C. A. Taylor (3909568)

PRRSV enters MARC-145 cells via macropinocytosis and rottlerin blocks the macropinocytosis by decreasing actin polymerization. by Yeonglim Kang (21395261)

RcbA and RcbB co-operatively decrease motility independent of CaCl₂ concentration. by Shobnom Mustaree (21728815)

Data Sheet 1_Elevated relative humidity significantly decreases cannabinoid concentrations while delaying flowering development in Cannabis sativa L..docx by Ingrid Carolina Corredor-Perilla (22631510)

“…Furthermore, high RH significantly suppressed cannabinoid accumulation: cannabidiolic acid (CBD-A), cannabidiol (CBD), and cannabichromenic acid (CBC-A) levels decreased by approximately 4.9-fold, 3.2-fold, and 13-fold, respectively. …”

DHE reports decreased cholesterol uptake by ∆<i>mceG</i> Mtb. by Yue Chen (73753)

TITAN decreaser diatom heatmap. by Brent J. Bellinger (21156150)

Inotodiol decreases clone formation in HCC cells. by Yushuang Xing (20636685)

“…In addition, inotodiol showed to induce apoptosis, characterized by an increase in Bax expression, a decrease in Bcl-2, Bcl-XL and MCL1 expression, the initiation of cleaved PARP1 and cleaved caspase 3, and inhibition of the MAPK/ERK pathway. …”

Inotodiol decreases clone formation in HCC cells. by Yushuang Xing (20636685)

IFN-γ and several PARP genes are upregulated in infected olfactory bulbs of JHMV infected mice. by Catherine M. Kerr (21492574)

Analysis of tea output value distribution and growth- decrease rate of provinces. by Kun Qin (177235)

Table 1_PARP inhibition increases sensitivity to cisplatin in non-small-cell lung carcinoma via the induction of TET-dependent hydroxymethylation.xlsx by Nevena Grdović (394542)

“…Treatment of A549 cells with niraparib resulted in decreased PARP activity, increased 5hmC level, and synergism with cisplatin by promoting cisplatin-induced apoptosis. …”

Data Sheet 1_PARP inhibition increases sensitivity to cisplatin in non-small-cell lung carcinoma via the induction of TET-dependent hydroxymethylation.pdf by Nevena Grdović (394542)

“…Treatment of A549 cells with niraparib resulted in decreased PARP activity, increased 5hmC level, and synergism with cisplatin by promoting cisplatin-induced apoptosis. …”

Introgression decreases allelic shuffling. by Enrique J. Schwarzkopf (6579275)

Top 20 IPA pathways of 2405 genes downregulated following KA treatment with a <i>P</i>-value of < 0.05. by Naoto Arimura (416442)

List of DEGs via FC values. by Zi-Yun Yi (19859589)

Characterization of cisplatin resistance phenotype in A2780 and A2780cp cells. by Hadi Alizadeh (20854757)

Subjects:

Diet composition and nutritional values. by Taynara Aparecida Vieira (16401726)

“…After developing cardiac remodeling, the animals were again distributed into three groups to receive BLE (50 mg/kg/day) or placebo (water) via gavage for 10 weeks: C, HSF and HSF + BLE. The HSF group exhibited obesity (HSF 8.77 ± 2.64 <i><i>vs</i></i> C 3.09 ± 1.02, <i>p = </i>0.007), dyslipidemia (HSF 94.4 ± 19.1 <i><i>vs</i></i> C 26.7 ± 5.2, <i><i>p < </i></i>0.001), hypertension (HSF 141 ± 8 <i><i>vs</i></i> C 120 ± 4, <i>p = </i>0.001), insulin resistance (HSF 6.91 ± 1.38 <i><i>vs</i></i> C 2.47 ± 1.01, <i><i>p < </i></i>0.001), cardiac remodeling and dysfunction, cardiac inflammation, decreased metalloproteinase-2 (MMP-2) (HSF 0.43 ± 0.09 <i><i>vs</i></i> C 0.71 ± 0.07, <i>p = </i>0.009) and increased type III collagen (HSF 1.32 ± 0.27 <i><i>vs</i></i> C 1.00 ± 0.18, <i>p = </i>0.038). …”

Top 20 Ingenuity Pathway Analysis (IPA) pathways of 3382 genes upregulated following KA treatment with a <i>P</i>-value of < 0.05. by Naoto Arimura (416442)

Decrease in loss during the training process. by Muhammad Idrees (92773)